EP3843745A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY Download PDF

Info

Publication number
EP3843745A4
EP3843745A4 EP19855576.5A EP19855576A EP3843745A4 EP 3843745 A4 EP3843745 A4 EP 3843745A4 EP 19855576 A EP19855576 A EP 19855576A EP 3843745 A4 EP3843745 A4 EP 3843745A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
mammalian body
treating neuroblastoma
juvenile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19855576.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3843745A1 (en
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of EP3843745A1 publication Critical patent/EP3843745A1/en
Publication of EP3843745A4 publication Critical patent/EP3843745A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19855576.5A 2018-08-28 2019-08-28 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY Pending EP3843745A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723592P 2018-08-28 2018-08-28
PCT/US2019/048579 WO2020047103A1 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body

Publications (2)

Publication Number Publication Date
EP3843745A1 EP3843745A1 (en) 2021-07-07
EP3843745A4 true EP3843745A4 (en) 2022-06-15

Family

ID=69645361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19855576.5A Pending EP3843745A4 (en) 2018-08-28 2019-08-28 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY

Country Status (7)

Country Link
EP (1) EP3843745A4 (https=)
JP (1) JP7530351B2 (https=)
KR (1) KR102904381B1 (https=)
CN (1) CN113164491A (https=)
AU (1) AU2019330831B2 (https=)
CA (1) CA3111015A1 (https=)
WO (1) WO2020047103A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111345A1 (en) * 1999-12-06 2002-08-15 Paul Calabresi Use of taurolidine to treat tumors
WO2017123635A1 (en) * 2016-01-11 2017-07-20 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20180185378A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
WO2013190355A1 (en) * 2012-06-18 2013-12-27 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
CN106974901A (zh) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 洛铂在制备治疗神经母细胞瘤药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111345A1 (en) * 1999-12-06 2002-08-15 Paul Calabresi Use of taurolidine to treat tumors
WO2017123635A1 (en) * 2016-01-11 2017-07-20 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20180185378A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617] *
ESCHENBURG GEORG ET AL: "Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells", GENES & CANCER, vol. 5, no. 11-12, 9 October 2014 (2014-10-09), pages 460 - 469, XP055885452, DOI: 10.18632/genesandcancer.36 *
KENNETH WONG ET AL: "The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma", NANOTECHNOLOGY, SCIENCE AND APPLICATIONS, 1 June 2010 (2010-06-01), Macclesfield, pages 23 - 28, XP055698597, Retrieved from the Internet <URL:https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1590506359_5ecd33773d8ef/NSA-8224-the-cytotoxic-effects-of-lipidic-formulated-gold-porphyrin-n_061510�1!.pdf> DOI: 10.2147/NSA.S8224 *
See also references of WO2020047103A1 *

Also Published As

Publication number Publication date
JP7530351B2 (ja) 2024-08-07
AU2019330831B2 (en) 2025-10-30
CN113164491A (zh) 2021-07-23
AU2019330831A1 (en) 2021-04-29
KR102904381B1 (ko) 2025-12-31
JP2021535173A (ja) 2021-12-16
EP3843745A1 (en) 2021-07-07
KR20210050543A (ko) 2021-05-07
CA3111015A1 (en) 2020-03-05
WO2020047103A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
EP3947715A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3894392A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d&#39;utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d&#39;utilisation pour le traitement du cancer
MA45341A (fr) Procédés de traitement de malignités de lymphocytes b au moyen d&#39;une thérapie cellulaire adoptive
FR23C1015I1 (fr) Procédés de sélection d&#39;une lignée de lymphocytes t et donneur de lignée de lymphocytes t pour thérapie cellulaire adoptive
MA47208A (fr) Procédés de traitement du cancer à l&#39;aide d&#39;anticorps anti-pd-1
EP3555077A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
MA71705A (fr) Substances et procédés pour le traitement d&#39;hémoglobinopathies
EP3846846A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
MX389945B (es) Anticuerpos anti-pd-1 y sus metodos de uso.
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3443013A4 (en) METHOD FOR USE OF PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
EP3400013A4 (en) CADHERIN-17 SPECIFIC ANTIBODIES AND CYTOTOXIC CELL TREATMENT CELLS
EP3370741A4 (en) METHOD AND COMPOSITIONS FOR GENETIZING BLOOD-GENERATING STEM CELLS
EP3364997A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM BALANCE IN NEURODEEGENERATIVE DISEASES
EP3635100A4 (en) COMPOSITIONS AND METHOD OF EXPRESSION OF OTOFERLIN
EP3624896A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
EP3377516A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3402483A4 (en) METHOD AND COMPOSITIONS FOR ACTIVATING GAMMA DELTA T CELLS
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP2983791A4 (en) METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
EP3973047A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASES
MA52971A (fr) Compositions et procédés pour le traitement de l&#39;infiltration de graisse dans le muscle

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220517

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20220511BHEP

Ipc: A61K 31/00 20060101ALI20220511BHEP

Ipc: A61K 31/198 20060101ALI20220511BHEP

Ipc: A61P 35/00 20060101ALI20220511BHEP

Ipc: A61K 47/60 20170101ALI20220511BHEP

Ipc: A61K 47/10 20170101ALI20220511BHEP

Ipc: A61K 35/00 20060101ALI20220511BHEP

Ipc: A61K 33/243 20190101ALI20220511BHEP

Ipc: A61K 31/675 20060101ALI20220511BHEP

Ipc: A61K 31/555 20060101ALI20220511BHEP

Ipc: A61K 31/475 20060101ALI20220511BHEP

Ipc: A61K 31/4745 20060101ALI20220511BHEP

Ipc: A61K 9/14 20060101ALI20220511BHEP

Ipc: A61K 31/549 20060101ALI20220511BHEP

Ipc: A61K 31/541 20060101ALI20220511BHEP

Ipc: A61K 31/54 20060101AFI20220511BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250506